DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar
disorder during treatment with lithium and divalproex.
JAMA, 2003, 290:1467–1473.
Gothelf D, Falk B, Singer P, et al. Weight gain associated with
increased food intake and low habitual activity levels in male
adolescent schizophrenic inpatients treated with olanzapine.
Am J Psychiatry, 2002, 159:1055–1057.
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition
and functional outcome in schizophrenia: implications for
MATRICS. Schizophrenia Res, 2004, 72:41–51.
Gründer G, Hippius H, Carlsson A. The “atypicality” of antipsychotics:
A concept re- examined and re- defined. Nat Rev Drug
Disc, 2009, 8:197–202.
Hahn CG, Gyulai L, Baldassano CF, Lenox RH. The current
understanding of lamotrigine as a mood stabilizer. J Clin
Psychiatry, 2004, 65:791–804.
Hopkins HS, Gelenberg AJ. Serum lithium levels and the outcome
of maintenance therapy of bipolar disorder. Bipolar
Disord, 2000, 2:174–179.
Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute
effects of atypical antipsychotics on whole body insulin resistance
in rats: Implications for adverse metabolic effects.
Neuropsychopharmacology, 2007, 32:289–297.
Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic
deficiency hypothesis in delirium: A synthesis of current evidence.
J Gerontol Series A Biol Sci Med Sci, 2008, 63:
764–772.
Hummel B, Dittmann S, Forsthoff A, et al. Clozapine as add- on
medication in the maintenance treatment of bipolar and
schizoaffective disorders. A case series. Neuropsychobiology,
2002, 45(Suppl 1):37–42.
Janowsky DS, Davis JM. Antipsychotic properties of muscarinic
drugs. Am J Psychiatry, 2009, 166:110.
Jefferson JW. Lithium- associated clinical hypothyroidism. Int
Drug Ther Newsletter, 2000, 35:84–86.
Jefferson JW, Greist JH, Clagnaz PJ, et al. Effect of strenuous
exercise on serum lithium level in man. Am J Psychiatry, 1982,
139:1593–1595.
Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine,
a potent norepinephrine reuptake inhibitor and partial 5-HT1A
agonist, as a putative mediator of quetiapine’s antidepressant
activity. Neuropsychopharmacology, 2008, 33:2303–2312.
Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update
on use of antipsychotic drugs in elderly persons with dementia.
Neuropsychopharmacology, 2008, 33:957–970.
Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors
for new- onset diabetes mellitus and diabetic ketoacidosis associated
with atypical antipsychotics: An analysis of 45 published
cases. Ann Clin Psychiatry, 2002, 14:59–64.
Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose
dysregulation: A systematic review. Schizophrenia Res, 2004,
71:195–212.
Jope RS. A bimodal model of the mechanism of action of
lithium. Mol Psychiatry, 1999, 4:21–25.
Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic
status of bipolar I vs. bipolar II disorders. Int J
Neuropsychopharmacol, 2003, 6:127–137.
Juurlink DN, Mamdani MM, Kopp A, et al. Drug- induced
lithium toxicity in the elderly: A population- based study. J Am
Geriatr Soc, 2004, 52:794–798.
Kapur S, Zipursky R, Jones C, et al. Relationship between
dopamine D(2) occupancy, clinical response, and side effects:
A double- blind PET study of first- episode schizophrenia. Am
J Psychiatry, 2000b, 157:514–520.
Kapur S, Zipursky RB, Remington G. Clinical and theoretical
implications of 5-HT2 and D2 receptor occupancy of clozapine,
risperidone, and olanzapine in schizophrenia. Am J
Psychiatry, 1999, 156:286–293.
Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole
monotherapy for maintenance therapy in bipolar I disorder: a
100-week, double- blind study versus placebo. J Clin Psychiatry,
2007, 68:1480–1491.
Keck PE Jr, McElroy SL. Bipolar disorder, obesity, and
pharmacotherapy- associated weight gain. J Clin Psychiatry,
2003, 64:1426–1435.
Kim SF, Huang AS, Snowman AM, et al. Antipsychotic druginduced
weight gain mediated by histamine H1 receptor- linked
activation of hypothalamic AMP- kinase. Proc Natl Acad Sci
USA, 2007, 104:3456–3459.
Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium- induced
subclinical hypothyroidism: Review of the literature and guidelines
for treatment. J Clin Psychiatry, 1999, 60:249–255.
Kosten TR, Forrest JN. Treatment of severe lithium- induced
polyuria with amiloride. Am J Psychiatry, 1986, 143:
1563–1568.
Kozikowski AP, Gaisina IN, Yuan H, et al. Structure-based design
leads to the identification of lithium mimetics that block manialike
effects in rodents. possible new GSK-3beta therapies for
bipolar disorders. J Am Chem Soc, 2007, 129: 8328–8332.
Krivoy A, Fischel T, Weizman A. The possible involvement of
metabotropic glutamate receptors in schizophrenia. Eur
Neuropsychopharmacol, 2008, 18:395–405.
Kusalic M, Engelsmann F. Renal reactions to changes of lithium
dosage. Neuropsychobiology, 1996, 34:113–116.
Lacasse H, Perreault MM, Williamson DR. Systematic review
of antipsychotics for the treatment of hospital- associated delirium
in medically or surgically ill patients. Ann Pharmacother,
2006, 40:1966–1973.
Lenox RH, Wang L. Molecular basis of lithium action: integration
of lithium- responsive signaling and gene expression networks.
Mol Psychiatry, 2003, 8:135–144.
Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in
schizophrenia with new- generation antipsychotics: A systematic
review and exploratory meta- analysis of randomized, controlled
trials. Am J Psychiatry, 2003, 160:1209–1222.
Leucht S, Corves C, Arbter D, et al. Second-generation versus
first- generation antipsychotic drugs for schizophrenia: A metaanalysis.
Lancet, 2009, 373:31–41.
Li Z, Huang M, Ichikawa J, et al. N- desmethylclozapine, a
major metabolite of clozapine, increases cortical acetylcholine
and dopamine release in vivo via stimulation of M1
muscarinic receptors. Neuropsychopharmacology, 2005, 30:
1986–1995.
Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic
drugs: Comparison in animal models of efficacy, neurotransmitter
regulation, and neuroprotection. Pharmacol Rev, 2008,
60:358–403.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of
antipsychotic drugs in patients with chronic schizophrenia.
N Engl J Med, 2005, 353:1209–1223.
CHAPTER 16
PHARMACOTHERAPY OF PSYCHOSIS AND MANIA
453